Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1391&sort=-abstract
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-abstract", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-abstract", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-abstract", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1390&sort=-abstract" }, "data": [ { "type": "Grant", "id": "8699", "attributes": { "award_id": "1R21AI166778-01", "title": "RBC-mediated mopping of cytokines for the treatment of pneumonia", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 8224, "first_name": "Kentner L.", "last_name": "Singleton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-24", "end_date": "2023-08-31", "award_amount": 203125, "principal_investigator": { "id": 22455, "first_name": "Jacob", "last_name": "Brenner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ SUMMARY Despite the advent of antibiotics and antivirals, pneumonia remains a major killer. In typical years, it kills >50,000 Americans, and in the last year, nearly 10x that amount due to COVID-19. The reason for these deaths is rarely because we cannot stop microbial expansion. Rather, it is due to the host response, in which local inflammation in the lungs causes a very high concentration of pro-inflammatory cytokines to spill into the blood, whereupon the cytokines travel to and damage remote organs. To eliminate excessive cytokines, many antibodies have been developed to bind and neutralize cytokines. However, these antibodies extravasate into the infected tissue (lungs), where they also inhibit the beneficial function of these cytokines, which is the orchestration of leukocytes to clear the microbes. To prevent this problem and the subsequent microbial overgrowth, there is a need to engineer therapeutics that only quench cytokines in the bloodstream, and not in the infected tissues that rely upon cytokines for microbial clearance. To accomplish this, we have developed RBC-Mops. RBC-Mops bind and quench cytokines, but only in the bloodstream, with no extravasation into infected tissues. We will build and test RBC-Mops across two Aims: In Aim 1, we will test RBC-Mops ability to bind their targets in vitro, evaluate for damage to RBCs themselves, and determine the pharmacokinetics and biodistribution of RBC-Mops in naive mice. In Aim 1, we will test RBC-Mops in the Klebsiella mouse model of pneumonia, evaluating benefits to the lungs and remote organs, while also investigating potential side effects. This R21 is designed to produce and validate the prototype RBC-Mop within 2 years. After that, we will apply for an R01 to further the translational potential of RBC-Mops and better understand their mechanisms. Eventually, we hope to develop a combination of RBC-Mops that can eliminate cytokines and other circulating toxins, to ameliorate a large range of acute illnesses, including viral pneumonia (COVID-19), sepsis, and sterile cytokine release syndromes produced by immunological therapies.", "keywords": [ "Acute", "Adherence", "Adult Respiratory Distress Syndrome", "Air Sacs", "American", "Animal Model", "Anti-Inflammatory Agents", "Antibiotics", "Antibodies", "Antiviral Agents", "Bacteria", "Bacterial DNA", "Bacterial Pneumonia", "Binding", "Binding Proteins", "Biodistribution", "Blood", "Blood Circulation", "Blood capillaries", "COVID-19", "Cause of Death", "Cell Therapy", "Cell surface", "Cells", "Cellular Assay", "Cessation of life", "Chimeric Proteins", "Complement 3b Receptors", "Creatinine", "Critical Care", "Cytolysis", "DNA", "Data", "Disease", "Distant", "Drug Delivery Systems", "Drug Kinetics", "Endothelial Cells", "Endotoxins", "Engineering", "Erythrocytes", "Extravasation", "Focal Infection", "GYPA gene", "HMGB Proteins", "HMGB1 gene", "Immune", "Immune response", "Immune system", "Immunotherapy", "In Vitro", "Infection", "Inflammation", "Inflammation Mediators", "Inflammatory", "Infusion procedures", "Interleukin-6", "Klebsiella", "Kupffer Cells", "Letters", "Leukocytes", "Liposomes", "Liver", "Lung", "Lung infections", "Measures", "Mediating", "Mediator of activation protein", "Mentors", "Methods", "Microbe", "Minority", "Mitochondrial DNA", "Monoclonal Antibodies", "Mus", "Organ", "Output", "Patients", "Physicians", "Pneumonia", "Positioning Attribute", "Production", "Property", "Protein Engineering", "Proteins", "Publishing", "Pulmonary Pathology", "Sepsis", "Site", "Sterility", "Surface", "T cell therapy", "TNF gene", "Technology", "Testing", "Therapeutic", "Therapeutic Effect", "Thrombomodulin", "Time", "Tissues", "Toxin", "Travel", "Viral Pneumonia", "Virus", "combat", "cytokine", "cytokine release syndrome", "design", "experience", "fighting", "lung injury", "microbial", "mouse model", "nanometer", "nanoparticle", "novel therapeutics", "particle", "pneumonia model", "pneumonia treatment", "preservation", "prevent", "prototype", "side effect", "therapeutic protein" ], "approved": true } }, { "type": "Grant", "id": "6711", "attributes": { "award_id": "1R01HL160694-01", "title": "Controlling complement to unleash nanomedicine for acute critical illnesses", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22454, "first_name": "GUOFEI", "last_name": "Zhou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-02-01", "end_date": "2026-01-31", "award_amount": 626215, "principal_investigator": { "id": 22455, "first_name": "Jacob", "last_name": "Brenner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22456, "first_name": "Vladimir R", "last_name": "Muzykantov", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 22457, "first_name": "Wenchao", "last_name": "Song", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ SUMMARY Acute critical illnesses rapidly lead to severe organ damage and loss of life. These illnesses include sepsis, stroke, and acute respiratory distress syndrome (ARDS). Here we focus on ARDS, which is acute inflammation of the lungs’ air sacs, and the cause of death in COVID-19. For ARDS and these other diseases, we have developed ligand-targeted nanocarriers that localize drugs to the inflamed microvasculature of affected organs. As we moved towards clinical translation, we found the key step is gaining control of complement, a set of plasma proteins that bind microbes and aid their clearance. But we found complement-nanoparticle interactions are a “double-edged sword”, with both benefits to optimize, and deleterious features to resolve. First, we found that complement protein C3 rapidly opsonizes particular nanoparticles, and that such C3- opsonized nanoparticles then act as “decoys” to ameliorate ARDS mouse models (e.g., nebulized LPS) by ~75%. The C3-coated nanoparticles accumulate in marginated leukocytes, which are key to ARDS pathophysiology, and cause those cells to leave the lungs. However, C3 opsonization induces an anaphylaxis-like reaction called CARPA (complement-activation-related pseudo-allergy). Therefore, in Aim 1, we will engineer nanoparticles that can function like C3-coated decoys to ameliorate ARDS, but without CARPA. We will also investigate the mechanism underlying nanoparticle decoy therapy. Then we will test the translational potential of these optimized decoy nanoparticles by testing them in fresh, perfused, ex vivo human lungs. Second, we found that the ligand-targeted nanoparticles we have been developing for drug delivery for years also induce CARPA. Therefore, in Aim 2, we will re-engineer our ligand-targeted nanoparticles to prevent CARPA. We will test a drug carrier we have previously used to concentrate drugs in the alveolar microvasculature of the lungs: liposomes conjugated to anti-PECAM antibodies that bind endothelial cells. We will test in vitro and in vivo in mice whether various engineered versions of anti-PECAM liposomes can evade C3 opsonization and CARPA, and thereby achieve more specific delivery to the lungs. Lastly, we will test these CARPA-avoiding nanoparticles with plasma from ARDS patients, as such patients have perturbed complement. Upon completion of these two Aims, we will have developed two technologies that may aid therapy of ARDS: 1) Decoy nanoparticles that safely cause marginated leukocytes to leave the lungs, and thereby ameliorate ARDS-like phenotypes; 2) A technology for preventing complement side effects such as CARPA when delivering ligand-targeted nanoparticles. As marginated leukocytes play pivotal roles in most acute critical illnesses, and CARPA sensitivity is common to those as well, the technologies developed here may impact not only ARDS, but also sepsis, stroke, and more.", "keywords": [ "Acute", "Acute Respiratory Distress Syndrome", "Adopted", "Affect", "Air Sacs", "Alveolar", "Alveolus", "Amino Acid Motifs", "Anaphylaxis", "Antibodies", "Artificial nanoparticles", "Binding", "Binding Proteins", "Biological Assay", "Blood", "Blood Proteins", "Blood capillaries", "C3bi", "COVID-19", "COVID-19 mortality", "Cause of Death", "Cells", "Cessation of life", "Complement", "Complement 3a", "Complement Activation", "Complement Factor H", "Complement component C1", "Critical Care", "Critical Illness", "Disease", "Drug Carriers", "Drug Delivery Systems", "Endothelial Cells", "Endothelium", "Engineering", "Functional disorder", "Genetic Complementation Test", "Human", "Hypersensitivity", "Hypotension", "Immune", "In Vitro", "Inflammatory", "Injections", "Knock-out", "Lead", "Leukocytes", "Life", "Ligands", "Liposomes", "Lung", "Macrophage-1 Antigen", "Malignant Neoplasms", "Measures", "Membrane Proteins", "Microbe", "Modeling", "Monoclonal Antibodies", "Mus", "Myocardial Infarction", "Nanotechnology", "Nebulizer", "Oleic Acids", "Organ", "Outcome", "Outpatients", "Patients", "Pharmaceutical Preparations", "Phenotype", "Physicians", "Plasma", "Plasma Proteins", "Play", "Properdin", "Pulmonary Inflammation", "Reaction", "Recombinants", "Reporting", "Role", "Sepsis", "Serum", "Side", "Spleen", "Stroke", "Technology", "Testing", "Therapeutic", "Therapeutic Effect", "Wild Type Mouse", "Work", "antibody conjugate", "base", "clinical translation", "complement 3 regulator", "complement pathway", "cytokine", "density", "design", "experimental study", "human tissue", "improved", "in vitro testing", "in vivo", "lung injury", "mouse model", "nanocarrier", "nanomedicine", "nanoparticle", "neutralizing antibody", "neutrophil", "prevent", "receptor", "side effect", "standard measure", "tissue resource", "translational potential", "uptake" ], "approved": true } }, { "type": "Grant", "id": "15819", "attributes": { "award_id": "1R21CA303350-01", "title": "A Pilot Study to Correlate 4-[18F]fluoro-1-naphthol PET/CT Imaging with Chronic Graft Versus Host Disease Manifestations", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 44227, "first_name": "YISONG", "last_name": "WANG", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-08", "end_date": "2027-08-31", "award_amount": 358605, "principal_investigator": { "id": 44228, "first_name": "George Liwei", "last_name": "Chen", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44229, "first_name": "David", "last_name": "Piwnica-Worms", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1420, "ror": "", "name": "UNIVERSITY OF TX MD ANDERSON CAN CTR", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "/ PROJECT SUMMARY Allogeneic hematopoietic cell transplant (alloHCT) is a curative therapy for many life-threatening hematologic malignancies but its full therapeutic potential is undermined by complications such as chronic graft-versus-host disease (GVHD). Chronic GVHD is the greatest cause of non- relapse mortality and develops in 25-50% of long-term survivors of alloHCT. Novel approaches are needed to diagnose and treat chronic GVHD after alloHCT. 4-[18F]fluoro-1-naphthol ([18F]4FN) is a novel radiotracer that is specific to high energy reactive oxygen and nitrogen species produced during the respiratory burst in the active innate immune system. The proposed pilot study will apply [18F]4FN PET/CT to 16 patients with joint and other manifestations of chronic GVHD to obtain preliminary estimates of the anatomic and temporal correlations between [18F]4FN PET/CT signal intensity / location and chronic GVHD manifestations. Although PET, CT, and MRI have previously been used to image chronic GVHD, our approach differs by the use of [18F]4FN which reflects the functional activity of the innate immunity as indicated by respiratory burst intensity in contrast to glucose uptake as in [18F]fluoro-2-deoxyglucose (FDG) PET or anatomical changes as in CT and MRI. Patients will receive one to three [18F]4FN PET/CT scans and six to twelve Chronic GVHD Assessments. Data from these endpoints will be used to calculate preliminary estimates of the utility of [18F]4FN PET/CT as a predictive and prognostic / pharmacodynamic biomarker. We will test the following hypotheses with our specific aims: 1) [18F]4FN PET/CT images correlate anatomically with chronic GVHD manifestations and selected [18F]4FN PET/CT images will precede chronic GVHD manifestation changes. 2) [18F]4FN PET/CT images will provide pharmacodynamic metrics for treatment of chronic GVHD. Information gained from this pilot study will form the scientific basis for a subsequent larger phase II imaging trial to evaluate [18F]4FN PET/CT as a quantitative, predictive, and prognostic / pharmacodynamic biomarker for chronic GVHD. [18F]4FN PET/CT could be applied to other inflammatory conditions such as acute GVHD and cytokine release syndrome / immune effector cell associated neurotoxicity syndrome after CAR T cell infusion, and rheumatologic diseases. This multiple principal investigator project combines the unique, complementary expertise of Drs. Chen (alloHCT, chronic GVHD) and Piwnica-Worms (molecular imaging, radiopharmaceuticals). In 2022-2023, MD Anderson Cancer Center performed 416 adult alloHCTs of which 13.5% developed chronic GVHD within 1 year.", "keywords": [ "Acute Graft Versus Host Disease", "Adult", "Affect", "Allogenic", "Anatomy", "Biological Markers", "Cancer Center", "Cause of Death", "Clinical", "Clinical Trials", "Connective Tissue", "Consensus Development", "Data", "Deoxyglucose", "Development", "Diagnosis", "Disease", "Disparate", "Early Diagnosis", "Elasticity", "Evaluation", "Feasibility Studies", "Fibrosis", "Functional impairment", "Goals", "Hematologic Neoplasms", "Hematopoietic Neoplasms", "Hematopoietic Stem Cell Transplantation", "Image", "Immune System Diseases", "Immune system", "Inflammation", "Inflammatory", "Infusion procedures", "Innate Immune System", "Interobserver Variability", "Intervention Studies", "Intervention Trial", "Investigation", "Joints", "Lesion", "Life", "Location", "Long-Term Survivors", "Macrophage", "Magnetic Resonance Imaging", "Measurement", "Measures", "Methods", "Modality", "Naphthols", "Natural Immunity", "Nitrogen", "Organ", "Oxygen", "PET positivity", "Pain", "Patient-Focused Outcomes", "Patients", "Pharmacodynamics", "Phase", "Phase Ia Trial", "Physical Examination", "Pilot Projects", "Positron-Emission Tomography", "Prediction of Response to Therapy", "Principal Investigator", "Radiopharmaceuticals", "Reaction", "Reporting", "Research", "Respiratory Burst", "Rheumatism", "Risk", "Safety", "Scanning", "Severities", "Signal Transduction", "Skin", "Skin Tissue", "Symptoms", "Testing", "Therapeutic", "Therapeutic Agents", "Tissues", "Transplant Recipients", "United States National Institutes of Health", "X-Ray Computed Tomography", "arthropathies", "chimeric antigen receptor T cells", "chronic graft versus host disease", "clinical imaging", "clinical phenotype", "curative treatments", "cytokine release syndrome", "design", "effective therapy", "functional status", "glucose uptake", "immune effector cell-associated neurotoxicity syndrome", "improved", "leukemia/lymphoma", "molecular imaging", "mortality", "novel", "novel strategies", "novel therapeutics", "pharmacodynamic biomarker", "physical symptom", "predicting response", "predictive marker", "prognostic", "radiotracer", "response", "spatiotemporal", "therapy development", "treatment response" ], "approved": true } }, { "type": "Grant", "id": "8899", "attributes": { "award_id": "5R01AG074946-02", "title": "Long-Term Effects of COVID-19 and Health Care Delivery Changes on Health Disparity Populations Living with Multiple Chronic Conditions", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8342, "first_name": "Marcel", "last_name": "Salive", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-30", "end_date": "2026-05-31", "award_amount": 504067, "principal_investigator": { "id": 24722, "first_name": "Nicole Jill", "last_name": "Cook", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 497, "ror": "https://ror.org/051fd9666", "name": "Case Western Reserve University", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24723, "first_name": "KURT C", "last_name": "STANGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 497, "ror": "https://ror.org/051fd9666", "name": "Case Western Reserve University", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "/ PROJECT SUMMARY People living with multiple chronic conditions (MCC) consume a high proportion of health care resources but are not well-served by one-disease-at-a-time scientific evidence and health care delivery systems. Primary care, focused on the whole person in their family and community context, has great but under-informed potential to integrate the care of people with MCC, particularly community health centers (CHCs) that focus on health disparity populations. The COVID-19 pandemic and resulting societal and health care system responses have uncovered tremendous care disparities, while also stimulating innovations with great potential to foster integrated personalized primary care for people with MCC in an otherwise fragmented, impersonal, inequitable health care system. In particular, telehealth visits in the context of ongoing person- focused relationships, integrated mental health services, and outreach to high-risk patients with MCC provide hope for advancing the equity and quality of care for health disparity populations. We have a unique opportunity to study the effects of the pandemic in a national network of 926 community health centers serving >2.6 million patients from health disparity populations. The proposed study will: 1) Identify evolving changes in health care delivery to people with MCC in community health centers in response to the continuing COVID-19 pandemic and its aftermath; 2) Assess the impact of these practice changes on care quality for people living with MCC; 3) Identify promising emerging strategies to improve health care for people living with MCC. We will conduct a time series analysis of practice changes and associated patient outcomes in response to the COVID-19 pandemic. Monthly analyses will examine changes in practice processes, patient outcomes, and workforce stability for health disparity populations and for people with and without multiple chronic conditions. For a five-year period going back to January 2020 ― the month of the first known COVID- 19 case in the US and the start of responding public health and practice changes ― we will analyze and publicly report, on a monthly basis, practice changes and patient outcomes, to rapidly inform decision making about primary care of health disparity populations with MCC. Subgroup analyses will examine differences across 26 states that have had different societal and policy responses to the pandemic. The findings from these quantitative analyses of millions of patients being seen in hundreds of community health centers will be used to identify a purposive sample of exemplars for in-depth case studies that put a face on the quantitative findings and identify and characterize practice innovations that show promise in reducing health care disparities and improving care for people living with MCC. Study findings will generate vital new knowledge on the effect of a pandemic on the quality and equity of care provided to people MCC and will inform efforts to improve health care equity after a natural disaster.", "keywords": [ "Acute", "Adoption", "Affect", "African American", "Area", "Back", "COVID-19", "COVID-19 pandemic", "Caring", "Case Study", "Chronic Care", "Chronic Disease", "Communities", "Community Health Networks", "Computerized Medical Record", "Consumption", "Country", "Data", "Decision Making", "Depression screen", "Disasters", "Disease", "Elderly", "Evolution", "Face", "Family", "Fostering", "Health", "Healthcare", "Healthcare Systems", "Home", "Human", "Information Technology", "Intervention", "Interview", "Knowledge", "Laboratories", "Language", "Latino", "Long-Term Effects", "Medicaid", "Mental Health Services", "Movement", "Natural Disasters", "Neighborhood Health Center", "Outcome", "Patient Care", "Patient-Focused Outcomes", "Patients", "Persons", "Policies", "Preventive measure", "Primary Health Care", "Process", "Provider", "Public Health Practice", "Quality of Care", "Refugees", "Reporting", "Research", "Resources", "Rural Health Centers", "Sampling", "Sampling Studies", "Seasonal Variations", "Subgroup", "System", "Time", "Time Series Analysis", "Visit", "acute care", "comparative", "disparity reduction", "follow-up", "functional status", "health care delivery", "health care disparity", "health care quality", "health disparity populations", "health inequalities", "high risk", "improved", "innovation", "insight", "interest", "long term consequences of COVID-19", "low socioeconomic status", "multiple chronic conditions", "novel", "outreach", "pandemic disease", "patient outreach", "patient registry", "practice-based research network", "remote visit", "response", "safety net", "secondary analysis", "service delivery", "social health determinants", "telehealth", "tool" ], "approved": true } }, { "type": "Grant", "id": "8900", "attributes": { "award_id": "1R01AG074946-01", "title": "Long-Term Effects of COVID-19 and Health Care Delivery Changes on Health Disparity Populations Living with Multiple Chronic Conditions", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8342, "first_name": "Marcel", "last_name": "Salive", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-30", "end_date": "2026-05-31", "award_amount": 536518, "principal_investigator": { "id": 24722, "first_name": "Nicole Jill", "last_name": "Cook", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 497, "ror": "https://ror.org/051fd9666", "name": "Case Western Reserve University", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24723, "first_name": "KURT C", "last_name": "STANGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 497, "ror": "https://ror.org/051fd9666", "name": "Case Western Reserve University", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "/ PROJECT SUMMARY People living with multiple chronic conditions (MCC) consume a high proportion of health care resources but are not well-served by one-disease-at-a-time scientific evidence and health care delivery systems. Primary care, focused on the whole person in their family and community context, has great but under-informed potential to integrate the care of people with MCC, particularly community health centers (CHCs) that focus on health disparity populations. The COVID-19 pandemic and resulting societal and health care system responses have uncovered tremendous care disparities, while also stimulating innovations with great potential to foster integrated personalized primary care for people with MCC in an otherwise fragmented, impersonal, inequitable health care system. In particular, telehealth visits in the context of ongoing person- focused relationships, integrated mental health services, and outreach to high-risk patients with MCC provide hope for advancing the equity and quality of care for health disparity populations. We have a unique opportunity to study the effects of the pandemic in a national network of 926 community health centers serving >2.6 million patients from health disparity populations. The proposed study will: 1) Identify evolving changes in health care delivery to people with MCC in community health centers in response to the continuing COVID-19 pandemic and its aftermath; 2) Assess the impact of these practice changes on care quality for people living with MCC; 3) Identify promising emerging strategies to improve health care for people living with MCC. We will conduct a time series analysis of practice changes and associated patient outcomes in response to the COVID-19 pandemic. Monthly analyses will examine changes in practice processes, patient outcomes, and workforce stability for health disparity populations and for people with and without multiple chronic conditions. For a five-year period going back to January 2020 ― the month of the first known COVID- 19 case in the US and the start of responding public health and practice changes ― we will analyze and publicly report, on a monthly basis, practice changes and patient outcomes, to rapidly inform decision making about primary care of health disparity populations with MCC. Subgroup analyses will examine differences across 26 states that have had different societal and policy responses to the pandemic. The findings from these quantitative analyses of millions of patients being seen in hundreds of community health centers will be used to identify a purposive sample of exemplars for in-depth case studies that put a face on the quantitative findings and identify and characterize practice innovations that show promise in reducing health care disparities and improving care for people living with MCC. Study findings will generate vital new knowledge on the effect of a pandemic on the quality and equity of care provided to people MCC and will inform efforts to improve health care equity after a natural disaster.", "keywords": [ "Acute", "Adoption", "Affect", "African American", "Area", "Back", "COVID-19", "COVID-19 pandemic", "Caring", "Case Study", "Chronic Care", "Chronic Disease", "Communities", "Community Health Networks", "Computerized Medical Record", "Consumption", "Country", "Data", "Decision Making", "Depression screen", "Disasters", "Disease", "Elderly", "Evolution", "Face", "Family", "Fostering", "Health", "Healthcare", "Healthcare Systems", "Home", "Human", "Information Technology", "Intervention", "Interview", "Knowledge", "Laboratories", "Language", "Latino", "Long-Term Effects", "Medicaid", "Mental Health Services", "Movement", "Natural Disasters", "Neighborhood Health Center", "Outcome", "Patient Care", "Patient-Focused Outcomes", "Patients", "Persons", "Policies", "Preventive measure", "Primary Health Care", "Process", "Provider", "Public Health Practice", "Quality of Care", "Refugees", "Reporting", "Research", "Resources", "Rural Health Centers", "Sampling", "Sampling Studies", "Seasonal Variations", "Subgroup", "System", "Time", "Time Series Analysis", "Visit", "acute care", "comparative", "disparity reduction", "follow-up", "functional status", "health care delivery", "health care disparity", "health care quality", "health disparity populations", "health inequalities", "high risk", "improved", "innovation", "insight", "interest", "low socioeconomic status", "multiple chronic conditions", "novel", "outreach", "pandemic disease", "patient outreach", "patient registry", "practice-based research network", "remote visit", "response", "safety net", "secondary analysis", "service delivery", "social health determinants", "telehealth", "tool" ], "approved": true } }, { "type": "Grant", "id": "8739", "attributes": { "award_id": "1U01DA055343-01", "title": "1/2 Assessing the Cumulative Impact of Early Life Substance and Environment Exposure on Child Neurodevelopment and Health", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 12931, "first_name": "Janani", "last_name": "Prabhakar", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-30", "end_date": "2022-05-31", "award_amount": 11790, "principal_investigator": { "id": 21629, "first_name": "Viren Andrew", "last_name": "D'Sa", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1416, "ror": "https://ror.org/01aw9fv09", "name": "Rhode Island Hospital", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 21630, "first_name": "Sean CL", "last_name": "Deoni", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1416, "ror": "https://ror.org/01aw9fv09", "name": "Rhode Island Hospital", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "/ DESCRIPTION What are the neurodevelopmental sequelae of in utero opiate and other substance exposure? The succinct nature of this question masks the complex and multifaceted nature of human neurodevelopment, and the diversity of environmental influences that can mediate or moderate the initial direct effects substances may have on the developing brain. From conception to age 10, our brain undergoes remarkable structural and functional growth. Neurodevelopmental processes that include myelination and synaptogenesis are at their peak, responding to integrative cascades of genetic and environmental interactions as they mature neural systems and provide the foundation for emerging cognitive and behavioral skills. The patterns of this early development reflects adaptation to the child's direct and contextual environments and, thus, the potential impact of in utero substance exposures must be considered within the broader family, psychosocial, economic, and physical environment. Over the past year, these environments have witnessed unprecedented upheaval as a result of the COVID-19 pandemic, impacting children, families, and pregnant individuals with disproportionate impact on lower-income, and racial and ethnic minority families - the very families already shaken by the ongoing opioid crisis. Our proposal aims to understand the neurodevelopmental impact of these converging experiences. We will collect deep multi-level and repeat neuroimaging and behavioral phenotype data, alongside rich contextual measures of environmental exposures centered on the child's lived experience, including social equity and socioeconomic factors. Building from a central hypothesis that brain development is an integrative process that is shaped by prenatal insults (opiate and other substance exposures) and ongoing postnatal influences against a backdrop of social,economic, and health inequalities we will: 1. Characterize the variability of `neurotypical' development, recognizing that multiple pathways reflecting individual adaption may lead to the same outcomes; 2. Examine how in utero substance exposures alter these patterns and pathways; and 3. Take a holistic and integrated approach to understanding how the diversity of a child's environment shapes and modifies brain patterns and outcomes. Achievement of these aims requires a careful and purposefully planned study with unbiased measures, community partners, and representative socioeconomic and demographic populations - communities with well-founded distrust of research and public health workers. At the heart of our proposal is the principle of access. We will reduce traditional barriers to participation using innovative data collection methods and mobile labs to bring the research to under-represented and marginalized communities; and build trusted connections with our participating families through our established community advisory boards and peer navigator networks. Our approach, therefore, aims to clarify the impact of substance exposure on child development whilst shifting the field of developmental neuroscience and substance use to a more equitable standard of research, with generalizable findings that can guide non-punitive public health policies.", "keywords": [ "Achievement", "Address", "Affect", "Age", "Analgesics", "Area", "Attention", "Attitude", "Behavioral", "Birth", "Brain", "COVID-19", "COVID-19 pandemic", "California", "Child", "Child Development", "Childhood", "Cognitive", "Communication", "Communities", "Complex", "Conceptions", "County", "Data", "Data Collection", "Development", "Economics", "Electrocardiogram", "Electroencephalography", "Environment", "Environmental Exposure", "Environmental Risk Factor", "Epidemiologic Methods", "Family", "Fentanyl", "Foundations", "Frequencies", "Genetic", "Genotype", "Growth", "Health", "Health Care Research", "Health Policy", "Health Services", "Heart", "Heroin", "Home", "Human Characteristics", "Individual", "Infant", "Lead", "Learning", "Life", "Light", "Low income", "Magnetic Resonance Imaging", "Masks", "Measurement", "Measures", "Mediating", "Memory", "Methods", "Mother-Child Relations", "National Institute of Drug Abuse", "Nature", "Neighborhoods", "Neonatal Abstinence Syndrome", "Neurocognitive", "Neurosciences", "New England", "Newborn Infant", "Nutritional", "Opioid", "Outcome", "Parent-Child Relations", "Participant", "Pathway interactions", "Pattern", "Physical environment", "Physiology", "Play", "Population", "Process", "Protocols documentation", "Public Health", "Recording of previous events", "Research", "Resources", "Rhode Island", "Sampling", "Sampling Studies", "Science", "Selection Bias", "Services", "Shapes", "Site", "Sleep", "Socioeconomic Factors", "Structure", "Substance Withdrawal Syndrome", "System", "Time", "Tissues", "Trust", "base", "behavioral phenotyping", "brain shape", "caregiving", "cognitive neuroscience", "community engagement", "data harmonization", "demographics", "distrust", "early childhood", "economic disparity", "ethnic minority population", "experience", "fetal", "fetal substance exposure", "health equity", "health inequalities", "high dimensionality", "in utero", "infancy", "innovation", "multimodality", "myelination", "neurobehavior", "neurodevelopment", "neuroimaging", "nutrition", "opioid epidemic", "peer", "phenotypic data", "postnatal", "pregnant", "prenatal", "prenatal exposure", "psychosocial", "racial disparity", "racial equality", "racial minority", "racism", "relating to nervous system", "repository", "skills", "social", "social capital", "social equality", "socioeconomics", "study population", "substance use", "synaptogenesis", "treatment services", "visual tracking" ], "approved": true } }, { "type": "Grant", "id": "6438", "attributes": { "award_id": "3R34DA050284-02S1", "title": "1/5 The Cumulative Risk of Substance Exposure and Early Life Adversity on Child Health Development and Outcomes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 21627, "first_name": "Vani", "last_name": "Pariyadath", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-09-30", "end_date": "2021-03-31", "award_amount": 126761, "principal_investigator": { "id": 21628, "first_name": "DIMA", "last_name": "AMSO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1416, "ror": "https://ror.org/01aw9fv09", "name": "Rhode Island Hospital", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 21629, "first_name": "Viren Andrew", "last_name": "D'Sa", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1416, "ror": "https://ror.org/01aw9fv09", "name": "Rhode Island Hospital", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true } ] }, { "id": 21630, "first_name": "Sean CL", "last_name": "Deoni", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 21631, "first_name": "HANS-GEORG", "last_name": "MUELLER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1416, "ror": "https://ror.org/01aw9fv09", "name": "Rhode Island Hospital", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "/ DESCRIPTION Does maternal infection by the SARS-CoV-2 virus during pregnancy harm the developing fetal brain or increase the sensitivity to later developmental and environmental insults? he novel coronavirus (Covid-19) outbreak has fundamentally altered the child health landscape, ushering in sweeping changes in the social and economic fabric within which children grow. The rapidity of these environment changes, coupled with the relatively novelty of the SARS-CoV-2 virus and the widespread nature of infections, have presented multiple pressing questions. Among the unknowns that directly affect newborn and child health are: 1. How does Covid-19 infection during pregnancy effect the developing fetus or subsequent infant neurodevelopment? And 2. How will the unprecedented scale and scope of concurrent environmental changes impact child health and neurodevelopment? Unfortunately, over the course of the outbreak, the impact on children has been slow to be recognized with studies of Covid-19 infection or effects in infants and young children sparse to nonexistent. Moreover, while the health and economic impacts of the Covid-19 outbreak have been felt by everyone, the most severe effects have be felt by racial and ethnic minorities and lower income families. Thus, the most sensitive families and children already at risk for worsened neurodevelopmental outcomes are disproportionately and more intensely affected. Studies of newborns and infants are, therefore, critical to designing effective guidelines of care for expectant mothers, optimizing early care and support for mothers and their newborns, and prioritizing pre- and postnatal interventions. This supplement proposal aims to contribute important and timely evidence for these outcomes by characterizing neurodevelopmental profiles in infants born to mothers with and without antenatal Covid-19 infection, and examining the concurrent impact of social, economic, and substance use factors. Building on two existing and on-going studies of infant neurodevelopment (R34DA050284 and UH3OD023313), with deeply characterised longitudinal neuroimaging, neurocognitive, socioeconomic, demographic, psychosocial and biospecimen data, we will first investigate differences in brain structure, function, and connectivity development from birth to 1yr of age in infants born to mothers who were infected by the SARS-CoV-2 virus during pregnancy and born between May 1, and Sept. 1, 2020, compared to infants recruited at the same time but to non-infected mothers. We will also examine the impact of infection timing during pregnancy and symptom severity on brain measures. Next, we will compare these brain development trends to data from children who turned 1year old prior to Jan. 1, 2020, allowing us to examine the impact of specific environmental factors, including maternal and infant stress, nutrition, sleep health, and parent- child interaction that have changed due to outbreak-related lock-down and social distancing polices. We will further look at these environmental factors through a racial and socioeconomic lens, examining differences across race and income dimensions.", "keywords": [ "2019-nCoV", "Address", "Affect", "Age", "Age-Months", "Alcohol or Other Drugs use", "Birth", "Brain", "Breast Feeding", "COVID-19", "COVID-19 pandemic", "Caring", "Child", "Child Development", "Child Health", "Cognitive", "Contracts", "Coupled", "Data", "Databases", "Development", "Dimensions", "Disease Outbreaks", "Economics", "Employee", "Environment", "Environmental Risk Factor", "Family", "Family history of", "Fetal Development", "Fetus", "Fever", "Growth", "Guidelines", "Health", "Hydrocephalus", "Hyperthermia", "Hypoxemia", "Image", "Income", "Individual", "Infant", "Infection", "Inflammation", "Inflammatory Response", "Intervention", "Kangaroo", "Lead", "Learning", "Life", "Longitudinal Studies", "Low income", "Measures", "Mediating", "Mothers", "Nature", "Neurocognitive", "Neurologic", "Newborn Infant", "Outcome", "Parent-Child Relations", "Pattern", "Play", "Police", "Pregnancy", "Pregnant Women", "Premature Birth", "Race", "Regression Analysis", "Research", "Rhode Island", "Risk", "Risk Factors", "Role", "Safety", "Schools", "Services", "Severities", "Skin", "Sleep", "Smell Perception", "Social Distance", "Stress", "Stroke", "Structure", "Support Groups", "Symptoms", "Taste Perception", "Textiles", "Time", "Uncertainty", "Vertical Disease Transmission", "Virus", "antenatal", "antenatal care", "cognitive development", "cognitive function", "cytokine release syndrome", "design", "early life adversity", "economic impact", "educational atmosphere", "emerging adult", "environmental change", "environmental stressor", "ethnic minority population", "experience", "fetal", "health economics", "infection rate", "lens", "lower income families", "maternal stress", "neonate", "neurodevelopment", "neuroimaging", "novel coronavirus", "nutrition", "physical conditioning", "postnatal", "psychosocial", "racial and ethnic", "racial minority", "recruit", "sleep health", "sleep quality", "social", "sociodemographics", "socioeconomics", "treatment services", "trend" ], "approved": true } }, { "type": "Grant", "id": "14821", "attributes": { "award_id": "3R43HL169087-01A1S1", "title": "A breakthrough mobile phone technology that aids in early detection of COPD - TABA fund supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26329, "first_name": "SIDDHARTH KAUP", "last_name": "Shenoy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-06-01", "end_date": "2024-09-14", "award_amount": 6500, "principal_investigator": { "id": 28354, "first_name": "David", "last_name": "Wolfson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2096, "ror": "", "name": "TELE-STETHOSCOPE INC.", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "/ Abstract: This application is for TABA funds as a supplement to the following phase I project. COPD is the fourth leading global killer, in part, because of the failure of frontline medicine to detect the disease. Poor early detection leads to unfavorable outcomes and high healthcare costs. Tele-stethoscope* or “TS” is novel technology that allows acoustic data captured from ordinary mobile phones to perform robust analysis of hemodynamics and pneumodynamics. TS is intended to be used in primary care particularly in Tele-health and before scheduled physical examination. Its purpose is to alert primary care physicians to the need for physical examination and possibly referral. In these situations, there are no other comparable testing options. TS has three important innovations. First, is a clinical use innovation which brings remote, impromptu patient evaluation to anyone with a smartphone. Customer discovery has validated both a workflow and reimbursement strategy consistent with commercial success. Further, FDA guidance suggests viability of agency clearance. Second is TS’s novel approach to making AI algorithms. TS uses acoustic data, captured by OEM phone microphones, into rigorous, physics-based features that describe organ hemodynamics and pneumodynamics. The features or independent variables are then used to create binary classification models with logistic regression. By relying on physics, TS never has to use neural networks or overfitting strategies that have raised concerns about data intensity, model stability, regulatory transparency and unknown reliability. The third innovation is that, by relying on passive acoustic data, TS classifies organ function by observing organ dynamics directly rather than from forced air capacity. TS uses many ideas from physics that were not available until fairly recently. By relying on dynamics, TS offers a novel approach to forced air that may eventually be additive to our understanding of respiratory conditions even in PFT labs. This will be the third large scale human study that demonstrates classification of cardio - pulmonary functionality. It follows a published study on COVID detection as well as soon to be published study on the ability of TS to reproduce echocardiogram estimates of ejection fraction. Analysis of stethoscope recordings suggests that the COPD diagnostic will rely on a combination of right heart side hemodynamics and low frequency lung pneumodynamics. A significant body of research is presented which validates the use of mobile phones as an auscultation device with the ability to detect and diagnosis COPD. The Aim of this study is to develop, evaluate, and test an algorithm that allows ordinary mobile phones to detect COPD. Our hypothesis is that TS technology can detect COPD by matching phone acoustic recordings to diagnosis. Diagnosis will be determined by a physician after considering gold standard testing. Performance of the models will be evaluated by using common statistical approaches such as area under the receiver operating curve AUC, sensitivity, specificity, accuracy. The research will have 3 milestones based on recruitment of 30, 60 and 100 patients respectively. Our approach is based on recruitment from patients assigned to a hospital PFT lab so that recordings and gold standard testing are done concurrently. Our team consists of a broad range of talent including the inventor of TS, pulmonology expertise, the research director of emergency medicine for the hospital running the tests, statistical expertise, and project management. * Tele-stethoscope or \"TS\" is patent pending technology developed by Fleming Scientific.", "keywords": [ "Acoustics", "Air", "Algorithms", "Area", "Auscultation", "COVID-19 detection", "Cardiopulmonary", "Cellular Phone", "Chronic Obstructive Pulmonary Disease", "Classification", "Clinical", "Data", "Devices", "Diagnosis", "Diagnostic", "Disease", "EFRAC", "Early Diagnosis", "Echocardiography", "Emergency Medicine", "Evaluation", "Failure", "Frequencies", "Funding", "Health Care Costs", "Heart", "Hospitals", "Image", "Legal patent", "Logistic Regressions", "Lung", "Lung Capacity", "Medicine", "Modeling", "Organ", "Outcome", "Patient Recruitments", "Patients", "Performance", "Phase", "Physical Examination", "Physicians", "Physics", "Primary Care", "Primary Care Physician", "Publishing", "Pulmonology", "Research", "Research Support", "Running", "Schedule", "Side", "Specificity", "Stethoscopes", "Talents", "Technology", "Telephone", "Testing", "artificial intelligence algorithm", "hemodynamics", "human study", "improved", "improved outcome", "innovation", "microphone", "neural network", "new technology", "novel", "novel strategies", "recruit", "respiratory", "success", "technology development", "telehealth" ], "approved": true } }, { "type": "Grant", "id": "5079", "attributes": { "award_id": "3K08NS101084-05S1", "title": "\"HSV1-Induced NMDA Receptor Encephalitis: a De Novo Murine Model of Autoimmune Encephalitis\"", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 18141, "first_name": "WILLIAM PATRICK", "last_name": "Daley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-18", "end_date": "2022-12-31", "award_amount": 66728, "principal_investigator": { "id": 18142, "first_name": "JENNY J", "last_name": "LINNOILA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT: The goals of this Mentored Clinical Scientist Research Career Development Award (K08) are to A) obtain theoretical and hands-on training in 1) rodent magnetic resonance (MR) and positron emission tomography (PET) molecular imaging and 2) virology and immunology, B) apply this training towards developing a rodent model of viral-induced autoimmune encephalitis, and C) to use the resulting data to create a successful R01 application in the final years of this K08. This award will be a crucial stepping-stone towards my overall goal of developing into an independent autoimmune neurologist that sees patients and studies these diseases in the laboratory, contributing to earlier diagnoses and better treatments for these disabling disorders. Autoimmune encephalitis can be fatal and can lead to significant disability. It is difficult to gather enough patients with autoimmune encephalitis for clinical trials. There is a published rodent model of NMDA receptor (NMDAR) encephalitis. However, it relies on the adoptive transfer of human anti-NMDAR antibodies into the brains of mice. In order to study the pathogenesis of these disorders, it would be particularly important to develop an animal model of NMDAR encephalitis which does not rely on exogenous antibodies. It has been recently recognized in humans that some cases of NMDAR encephalitis are triggered by herpes simplex virus (HSV) encephalitis. Rodent models of HSV encephalitis are established. Preliminary work by our lab showed that some mice with HSV encephalitis make anti-NMDAR antibodies. This research proposal aims to demonstrate the pathogenicity of these antibodies and to use this model to better understand the patho- physiology of NMDAR encephalitis. This will be done by using targeted molecular imaging to understand the mechanisms as well as profiling the immune responses involved in this autoimmune neurologic disorder. I am a board-certified Harvard-trained neurologist with specific clinical fellowship training in autoimmune neurology through the Mayo Clinic. I have obtained the top clinical training available in this field. Furthermore, I have gained additional experience in basic research within this topic by spending time in the laboratory of the renowned autoimmune neurologist Dr. Josep Dalmau, one of my co-mentors on this project. I bring a solid grounding in molecular biology, gained through my Ph.D. studies. In addition, I have a strong publication and funding record. The research career development plan outlined within this proposal will equip me with a better understanding of virology and immunology and the latest methodologies within these fields that can be applied to uncover the pathophysiology of parainfectious autoimmune neurologic disorders. The research environment across the MGH, Harvard, and MIT campuses is outstanding and my mentors have the relevant and necessary expertise to guide this career development plan. I am a full time faculty member in the Massachusetts General Hospital (MGH) Department of Neurology and an Instructor in Neurology at Harvard Medical School. I have the full backing of the chair of my department, Dr. Cudkowicz, to develop into an independent researcher.", "keywords": [ "Adoptive Transfer", "Animal Model", "Antibodies", "Autoimmune", "Autoimmune encephalitis", "Award", "Back", "Basic Science", "Brain", "Clinic", "Clinical", "Clinical Trials", "Data", "Development Plans", "Disease", "Doctor of Philosophy", "Early Diagnosis", "Early treatment", "Encephalitis", "Environment", "Faculty", "Fc Receptor", "Fellowship", "Functional disorder", "Funding", "General Hospitals", "Goals", "Herpes encephalitis", "Herpesvirus 1", "Hospital Departments", "Human", "Immune response", "Immunology", "K-Series Research Career Programs", "Laboratories", "Lead", "Magnetic Resonance", "Massachusetts", "Mentors", "Methodology", "Modeling", "Molecular Biology", "Molecular Target", "Mus", "N-Methyl-D-Aspartate Receptors", "Neurologist", "Neurology", "Pathogenesis", "Pathogenicity", "Patient-Focused Outcomes", "Patients", "Positron-Emission Tomography", "Publications", "Publishing", "Research", "Research Personnel", "Research Proposals", "Rodent", "Rodent Model", "Scientist", "Solid", "Time", "Training", "Viral", "Work", "career development", "disability", "experience", "improved", "instructor", "medical schools", "member", "molecular imaging", "mouse model", "nervous system disorder", "novel", "targeted biomarker", "targeted imaging", "virology" ], "approved": true } }, { "type": "Grant", "id": "12296", "attributes": { "award_id": "1C06OD036029-01", "title": "UNC BSL3 Core Facility", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 28173, "first_name": "YONG", "last_name": "Chen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-06", "end_date": "2028-05-31", "award_amount": 7916788, "principal_investigator": { "id": 28195, "first_name": "Craig A", "last_name": "Fletcher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT: The central goal of this project is to construct a 10,000 square feet biosafety level 3 (BSL3) research laboratory core facility to promote readiness to respond to future pandemics. Infectious diseases pose a severe and increasing threat to human health, especially in communities that lack access to health care. UNC programs will soon exceed current infrastructure capacity due to increase demand. A strategic review of our microbial pathogenesis and infectious disease community concluded that urgent action was essential to support the high containment programs. Among the barriers to the growth of research was a lack of access to critical technologies and animal space within the existing BSL3 laboratories. This transformative BSL3 core facility will allow UNC to expand to meet current and projected research needs in the UNC School of Medicine, School of Pharmacy, and Gillings School of Global Public Health. UNC has engaged multiple stakeholders across the research community to design and construct a centralized BSL3 suite to characterize the immune responses to coronavirus and other emerging viral pathogens and learn about what drives immune response, disease progression, and protection against future infection. The proposal will attain four objectives: 1. Design and construct a high containment facility to bring investigators working on emerging and re-emerging infections together; 2. Enable access to specialized instrumentation including aerobiology and imaging equipment for supporting high containment research; 3. Create institution-wide core space to allow recruitment of new investigators to the infectious disease research community by increasing usable laboratory space in the BSL3 facility and purchasing new equipment that will serve investigators within the many UNC centers, institutes, and departments and their nationwide collaborators; 4. Enhance UNC's ability to lead the rapid response generating new therapeutics and vaccines to save lives on a local, national, and even global level.", "keywords": [ "Animals", "Communicable Diseases", "Communities", "Containment", "Core Facility", "Coronavirus", "Disease Progression", "Equipment", "Future", "Gills", "Goals", "Growth", "Health", "Human", "Image", "Immune response", "Infection", "Infectious Diseases Research", "Infrastructure", "Institution", "Laboratories", "Laboratory Research", "Learning", "Pathogenesis", "Pharmacy Schools", "Public Health", "Readiness", "Research", "Research Personnel", "Research Project Grants", "Schools", "Technology", "biosafety level 3 facility", "design and construction", "future pandemic", "health care availability", "instrumentation", "medical schools", "microbial", "novel therapeutics", "novel vaccines", "pathogenic virus", "programs", "recruit", "response", "square foot", "usability" ], "approved": true } } ], "meta": { "pagination": { "page": 1391, "pages": 1424, "count": 14236 } } }